Histone Deacetylase Inhibition Has Targeted Clinical Benefit in ARID1A Mutated Advanced Urothelial Carcinoma

Molecular Cancer Therapeutics- United States

doi 10.1158/1535-7163.mct-17-0957

Full Text

Abstract

Available in

Date

Authors

Publisher

American Association for Cancer Research (AACR)

Related search

Mp71-12 Clinical Benefit of Platinum-Based Neoadjuvant Chemotherapy for Locally Advanced Upper Tract Urothelial Carcinoma

Journal of Urology
Urology
2017English

Molecular Sequelae of Histone Deacetylase Inhibition in Human Retinoblastoma Cell Lines: Clinical Implications

Investigative Ophthalmology and Visual Science
Molecular NeuroscienceOphthalmologySensory SystemsCellular
2009English

Metabolism as a Key to Histone Deacetylase Inhibition

Critical Reviews in Biochemistry and Molecular Biology
BiochemistryMolecular Biology
2011English

Histone Deacetylase Inhibition and Dietary Short-Chain Fatty Acids

ISRN Allergy
2011English

Cabozantinib in Combination With Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence

Molecular Cancer Therapeutics
Cancer ResearchOncology
2019English

Histone Deacetylase 6 (HDAC6); Histone Deacetylase 8 (HDAC8)

Science-Business eXchange
2013French

ARID1A-mutated Ovarian Cancers Depend on HDAC6 Activity

Nature Cell Biology
Cell Biology
2017English

Histone Deacetylase Inhibitors: Clinical Implications for Hematological Malignancies

Clinical Epigenetics
GeneticsDevelopmental BiologyMolecular Biology
2010English

A Novel Histone Deacetylase Inhibitor, CKD5, Has Potent Anti-Cancer Effects in Glioblastoma

Oncotarget
Oncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy